Prostatic Neoplasms, Castration-Resistant Clinical Trial
— URANISOfficial title:
URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra-223 Dichloride Treated mCRPC Patients in a Real Life Setting in Germany.
Verified date | October 2021 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This observational prospective single arm cohort study is designed to assess overall survival, symptomatic skeletal event free survival and quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium- 223 under real life conditions. In addition, time to next tumor treatment (TTNT), mobility, quality of life and selfcare, independence in activities of daily living and safety will be assessed.
Status | Completed |
Enrollment | 86 |
Est. completion date | September 17, 2020 |
Est. primary completion date | June 30, 2020 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Male patients diagnosed with castration resistant adenocarcinoma of the prostate (CRPC) with symptomatic bone metastases without known visceral metastases - Decision to initiate treatment with Radium-223 was made as per investigator's routine treatment practice Exclusion Criteria: -Patients participating in an investigational program with interventions outside of routine clinical practice and also in all non-interventional studies focusing on Radium- 223-dichloride. |
Country | Name | City | State |
---|---|---|---|
Germany | Many Locations | Multiple Locations |
Lead Sponsor | Collaborator |
---|---|
Bayer |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS) | Up to 60 months | ||
Secondary | Evaluation of symptomatic skeletal event free survival (SSE-FS) of mCRPC patients | Up to 60 months | ||
Secondary | Estimation of the incidence of pathological fractures. | Up to 60 months | ||
Secondary | Time to next tumor treatment(s) (TTNT) | Up to 24 months | ||
Secondary | Incidence of treatment-emergent adverse events (TEAE) | Up to 30 days after last administration of Radium-223 | ||
Secondary | Quality of life as patient reported outcome estimated using Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire | The FACT-P questionnaire version 4 is a 39-item questionnaire consisting of five domains; 'Physical well-being', 'Social/Family well-being', 'Emotional well-being', 'Functional well-being' and 'Additional concerns' (consisting of items relating specifically to prostate cancer and/or its treatment) and uses a 0-4 Likert-scale. | Up to 60 months | |
Secondary | Activities of daily living assessed according to the Katz-Index | Up to 7 months | ||
Secondary | Body function assessed in dimensions of "mobility", "self-care" and "domestic life" using the Medical Oncology Status in Europe Survey (MOSES) questionnaire | Up to 7 months | ||
Secondary | Estimation of the non-pathological fractures | Up to 60 months | ||
Secondary | Estimation of the bone associated events | Up to 60 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03325127 -
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
|
||
Withdrawn |
NCT02906605 -
A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05743621 -
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02204072 -
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
|
Phase 1 | |
Recruiting |
NCT05393791 -
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
|
Phase 2 | |
Completed |
NCT03927391 -
Effect of a Reduced Dose Enzalutamide in Frail (m)CRPC Patients on Cognitive Side Effects
|
Phase 4 | |
Recruiting |
NCT06353386 -
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03431350 -
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03822845 -
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02162836 -
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 1 | |
Completed |
NCT02899104 -
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
|
||
Active, not recruiting |
NCT04381832 -
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03563014 -
A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223
|
||
Active, not recruiting |
NCT05968599 -
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
|
||
Active, not recruiting |
NCT02803437 -
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
|
||
Recruiting |
NCT05944237 -
HTL0039732 in Participants With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03173859 -
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
|
Phase 2 | |
Terminated |
NCT02057666 -
Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04717154 -
Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer
|
Phase 2 |